BidaskClub downgraded shares of Merus (NASDAQ:MRUS) from a hold rating to a sell rating in a research report report published on Friday morning.

MRUS has been the subject of a number of other research reports. Zacks Investment Research raised shares of Merus from a hold rating to a strong-buy rating and set a $24.00 target price for the company in a research report on Thursday, June 28th. ValuEngine lowered shares of Merus from a buy rating to a hold rating in a research report on Tuesday, June 26th. Finally, Wedbush reissued an outperform rating and set a $34.00 target price (up previously from $26.00) on shares of Merus in a research report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Merus presently has a consensus rating of Hold and a consensus target price of $28.50.

Merus stock traded down $0.32 on Friday, reaching $15.71. 14,425 shares of the stock were exchanged, compared to its average volume of 45,308. The firm has a market cap of $446.61 million, a price-to-earnings ratio of -3.66 and a beta of -0.19. Merus has a twelve month low of $14.05 and a twelve month high of $26.74.

Merus (NASDAQ:MRUS) last released its earnings results on Thursday, July 26th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.33. The firm had revenue of $11.84 million during the quarter, compared to analyst estimates of $3.47 million. Merus had a negative net margin of 178.79% and a negative return on equity of 67.34%. Analysts forecast that Merus will post -2.6 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Aquilo Capital Management LLC acquired a new position in shares of Merus during the second quarter valued at about $28,470,000. Stanley Laman Group Ltd. raised its position in shares of Merus by 23.7% during the second quarter. Stanley Laman Group Ltd. now owns 57,396 shares of the biotechnology company’s stock valued at $1,306,000 after buying an additional 10,982 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Merus by 26.8% during the second quarter. Renaissance Technologies LLC now owns 48,200 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 10,200 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Merus during the first quarter valued at about $267,000. Finally, DRW Securities LLC acquired a new position in shares of Merus during the second quarter valued at about $286,000. 54.43% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Article: What is the Ex-Dividend Date in Investing?

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.